ArticleFrontiers in oncology2026
Prognostic value of a modified lymph node ratio for combined colorectal cancer tumour deposits: a population-based study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumour deposits (TDs) without metastatic lymph nodes are classified as N1c in the 8th edition of the AJCC staging manual. However, the prognostic value of TDs and lymph node ratio (LNR) in stage III colorectal cancer (CRC) remains unclear. This study aimed to compare the prognostic significance of TD count and LNR with the newly developed modified lymph node ratio (mLNR), and to create a prognostic nomogram integrating mLNR for stage III CRC patients. Methods: Using the SEER database, a training cohort of 25,689 stage III CRC patients was identified, alongside an external validation cohort of 563 patients from a hospital in China. Modified lymph node ratio (mLNR) was defined by combining TD count and LNR. The effects of TDs, LNR, and mLNR on cancer-specific survival (CSS) and overall survival (OS) were evaluated using Kaplan-Meier curves and Cox regression models. A nomogram incorporating mLNR was developed for prognosis prediction. Results: In both cohorts, TDs positivity was associated with poorer CSS (all P < 0.001). Multiple TDs correlated with worse CSS than a single TD (training: HR, 1.978; validation: HR, 1.805). High mLNR indicated a significantly higher risk of CRC-specific death (training: HR, 2.421; validation: HR, 4.60). The nomogram incorporating mLNR demonstrated good discrimination and calibration in both cohorts. Conclusions: mLNR is an independent prognostic factor for stage III CRC. The nomogram combining mLNR can effectively identify high-risk patients, aiding treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.